Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022

Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022

• obe-cel: poster presentation in B-ALL and B-NHL patients
• AUTO1/22: poster presentation in pediatric ALL patients
• AUTO4: poster presentation in T-Cell Lymphoma patients

LONDON, November 3, 2022 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of three abstracts submitted to the American Society of Hematology (ASH) Annual Meeting, to be held December 10-13, 2022.

“We’re looking forward to presenting follow up data from three of our clinical trials at ASH this year. Obe-cel continues to show a potentially best-in-class profile across a number of indications, and we will be presenting the encouraging safety, efficacy and long-term follow up of obe-cel in relapsed/refractory B-ALL as well as in the B-NHL cohorts from the ALLCAR19 study,” said Dr. Christian Itin, Chief Executive Officer of Autolus. “For both AUTO1/22 in pediatric ALL patients and for AUTO4 in peripheral T Cell Lymphoma we will present longer follow up data.”

Abstracts to be presented:

1. Title: Safety, Efficiency and Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

LINK to abstract

Session Title: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II
Session date and time: Sunday, December 11, 2022, 6:00 PM – 8:00 PM

Session room: Ernest N. Morial Convention Center, Hall D

Publication Number:  3318

Presenting Author: Dr. Claire Roddie, MD, PhD, FRCPath, Consultant Haematologist and Honorary Senior Lecturer, Cancer Institute, University College London (UCL)

Summary: obe-cel (AUTO1) has demonstrated an excellent safety profile across 3 reported trials, with low levels of CRS/ICANS. Overall, obe-cel has a tolerable safety profile in patients with r/r B-cell cancers despite high disease burden. In the B-ALL cohort of the ALLCAR19 study, long-term follow-up indicates that a subset of patients continue in remission post- obe-cel without need for further anti-leukemia therapy. In both indolent and aggressive NHL and in CLL, obe-cel shows excellent ORR and CAR engraftment/persistence. Additional patients, updated data and longer follow up will be presented.

1. Title: Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL (AUTO1/22)

LINK to abstract

Session Title: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III

Session date and time: Monday, December 12, 2022, 6:00 PM – 8:00 PM

Session room: Ernest N. Morial Convention Center, Hall D

Publication Number:  4650

Presenting Author: Dr. Sara Ghorashian, MD, PhD, Hon clinical senior lecturer, UCL Great Ormond Street Institute of Child Health

Summary: CD19 negative escape is a major cause of relapse after CD19 CAR T cell therapy for relapsed/refractory (r/r) pediatric ALL. To overcome this challenge, AUTO1/22 builds on the favorable safety profile and excellent persistence of obe-cel by combining it with an additional CD22 targeting CAR. As of 21 July 2022, 12 pediatric ALL patients have been treated with AUTO1/22. Overall, at a median follow-up of 8.7 months (range 1-15 months), 6/10 responding patients remain in MRD negative CR at last follow-up. Importantly, antigen-negative relapse has not been observed.

1. Title: First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

LINK to abstract

Session Title: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III

Session date and time: Monday, December 12, 2022, 6:00 PM – 8:00 PM

Session room: Ernest N. Morial Convention Center, Hall D

Publication Number:  4634

Presenting Author: Dr Kate Cwynarski, Consultant Haematologist University College London Hospitals (UCLH)

Summary: Peripheral T cell lymphomas (PTCL) are typically aggressive, treatment resistant, and associated with poor prognosis. Finding the right target is challenging because there is a lack of tumor-specific antigens, and pan-T cell depletion leads to immunosuppression. T cell lymphoma is clonal, and tumor cells express either TRBC1 or TRBC2. AUTO4 targets TRBC1+ cells, which allows part of the T cell compartment to be retained. This study is ongoing, with additional patients due to be treated to define the recommended phase 2 dose using the new manufacturing process.